Health Technology Assessment, Price and Reimbursement Review for Orphan Drugs In France

Health Technology Assessment, Price and Reimbursement Review for Orphan Drugs In France

2014 Value in health

Korchagina, D. | Remuzat, C. | Rodrigues, J. | Kornfeld, A. | Toumi, M. | Volume: 17, Issue: 7, Pages: A540, France, orphan drug, Price, Value,

In France Orphan Drugs (OD) undergo the same Health Technology Assessment (HTA) procedure as other drugs. The evaluation is performed by the Transparency Committee (TC). Two scores are assigned and further used for pricing & reimbursement decision: drug’s medical benefit (SMR) and improvement in medical benefit (ASMR). OD can be eligible to an accelerated procedure established for innovative products. The study aim is to analyse HTA decisions, prices and reimbursement of OD in France.

https://www.doi.org/10.1016/j.jval.2014.08.1734; 10.1016/j.jval.2014.08.1734